RayzeBio (RYZB) Financial Analysis & Valuation | Quarter Chart
RayzeBio (RYZB)
RYZBPrice: $62.49
Fair Value: 🔒
🔒score
RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company’s lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary pept... more
RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The comp... more
Description
Shares
| Market Cap | $3.75B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Kenneth Song |
| IPO Date | 2023-09-15 | CAGR | — |
| Employees | 88 | Website | — |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
RYZB chart loading...
Fundamentals
Technicals
| Enterprise Value | $99.64M | P/E Ratio | -57.86 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | -22.02 |
| P/CF Ratio | -47.42 | P/FCF Ratio | -61.7 |
| EPS | $-1.08 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | 0.83% | ROA | -0.21% |
| ROCE | -0.23% | Current Ratio | 28.69 |
| Quick Ratio | 28.69 | Cash Ratio | 12.35 |
| Debt/Equity | -0.09 | Interest Coverage | — |
| Altman Z Score | — | Piotroski Score | — |